The Cann Group Ltd (ASX: CAN) share price has returned from its trading halt and rocketed higher.
In morning trade the cannabis company’s shares are up 25% to $1.26.
Why is the Cann Group share price rocketing higher on Tuesday?
Investors have been scrambling to buy Cann Group’s shares this morning after the release of a joint announcement with its manufacturing partner IDT Australia Limited (ASX: IDT).
According to the release, GMP extraction activities are underway for the first batches of medicinal cannabis resin.
This extracted resin will be used as an Active Pharmaceutical Ingredient (API) in formulation and packaging activities at IDT to produce GMP medicinal cannabis oil products. It will also be made available for purchase as an API.
Once formulated and packed, the cannabis oil products will undergo stability testing to support a targeted commercial release in late March of this year. Management notes that this is a key step in allowing finished products to be produced and released into the market at scale.
The release explains that the extracted resin will be formulated into a full range of GMP medicinal cannabis finished dosage form products. This includes formulations featuring high THC, high CBD and balanced formulations.
These products will be formulated and packed by IDT and made available via the Special Access Scheme (SAS) to Australian prescribers and patients. They will also be positioned for export to markets overseas.
Cann Group’s CEO, Peter Crock, believes this is a milestone for the company.
He said: “This facilitates the manufacture of finished product formulations and puts us a step closer to launching our own locally sourced and produced range of medicinal cannabis treatments to satisfy both domestic demand and to help develop valuable export pathways.”
Also on the rise this morning is the MGC Pharmaceuticals Ltd (ASX: MXC) share price. Its shares are up 6% following the announcement of the launch of a new cannabis product line in the ANZ market.
This Tiny ASX Stock Could Be the Next Afterpay
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting...
Because 'Doc' Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!
Returns as of 6th October 2020
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- 2 buy-rated small cap ASX shares for your watchlist – January 17, 2021 1:00pm
- Buy these ASX dividend shares if the RBA cuts rates again – January 17, 2021 9:58am
- Top brokers name 3 ASX shares to buy next week – January 17, 2021 9:00am